李富玉教授治疗高尿酸血症的临床研究
|
摘要
李富玉教授医德高尚,学验俱丰,在疑难杂症的诊断、治疗、预防等方面积累了丰富的经验,根据多年的临证经验,提出了“毒邪致病说”,认为疑难杂症多迁延难愈,是因毒邪滞留体内所致,可从毒论治。目前高尿酸血症发病率有逐年增加的趋势,李教授根据其形成原因、致病特点、流行病学调查等,并结合自己的临床研究心得,认为其基本病机是肾脏亏损、浊毒内蕴,浊毒贯穿于高尿酸血症的全过程,提出以补肾泄浊解毒为治则,并注重未病先防,既病防变,取得了较好的疗效。
本课题根据李富玉教授的临证经验,进行补肾泄浊解毒饮治疗高尿酸血症的临床研究。目的：通过观察补肾泄浊解毒饮和别嘌呤醇治疗高尿酸血症的临床疗效,及治疗前后对血尿酸(SUA)、尿尿酸(UUA)、尿pH值、血清总胆固醇(TCH)和甘油三酯(TG)等指标的影响,进而评价补肾泄浊解毒饮治疗高尿酸血症的临床疗效。方法：将符合高尿酸血症诊断标准的60例患者随机分为中药治疗组30例和别嘌呤醇组30例。中药治疗组给予补肾泄浊解毒饮,口服；西药对照组给予别嘌呤醇片,口服,4周为一个疗程,治疗一个疗程后观察治疗前后临床疗效,并对血尿酸、尿尿酸、尿pH值、血清总胆固醇和甘油三酯等指标进行比较。结果：中药治疗组临床总有效率93.3%,别嘌呤醇组临床总有效率90.0%,两组比较,无显著性差异(P>0.05)；中药治疗组和别嘌呤醇组两组在降低血尿酸方面,各自进行治疗前后的对比,均有显著性差异(P<0.05),但两组进行治疗后血尿酸水平的对比,则无显著性差异(P>0.05),在其他各项观察指标中,中药治疗组能增加尿尿酸的排泄,提高尿pH值,降低总胆固醇、甘油三酯,而别嘌呤醇组则无此作用。
结论：补肾泄浊解毒饮具有降低血尿酸的作用,其降低血尿酸的效果与别嘌呤醇相当,同时补肾泄浊解毒饮还有增加尿尿酸排泄、提高尿pH值、降低总胆固醇及甘油三酯等作用,因此,补肾泄浊解毒饮是治疗高尿酸血症的有效方药之一,值得进一步研究开发及推广应用。
Professor Li Fu-yu is a man of strong moral fiber and good medical technology. He has rich experience in diagnosis, treatment and prevention of difficult and complicated diseases. According to many years'clinical experience, he propounds a theory of diseases induced by Toxin. Recently, the rate of hyperuricemia has increased. Professor Li thinks difficult and complicated diseases are usually caused by toxin, so those diseases can be treated by relieving internal toxin. Hyperuricemia is also a subclinical disease. Based on the modern medical research in the formation mechanism, pathogenic characteristics and epidemiological investigation and Prof. Li's clinical experience, he proposes a view that the essential pathogenesis of hyperuricemia is kidney deficiency and toxin stasis. Toxin plays an important role in the development of hyperuricemia. Furthermore, he points out that tonifying the kidney and relieving internal toxin are two principles of treatment. He also emphasizes protection before the onset and preventing disease from exacerbating in the treatment of hyperuricemia.
This study was a clinical research aimed to evaluate the efficacy of tonifying the kidney and relieving internal toxin on the treatment of hyperuricemia. Objective:To observe the clinical efficacy of Bu-shen-xie-zhuo-jie-du decoction on hyperuricemia by comparison of uric acid, total cholesterol, triglyceride in the blood and acidum uricum, pH value in the urine before and after treatment. Methods:60 patients with a diagnosis of hyperuricemia were randomly divided into two groups. There are 30 patients in control group treated with allopurinol, and 30 patients in treatment group treated with herbal decoction. Four weeks was a treatment course. After a course, the clinical effects were evaluated and the indexes of uric acid, total cholesterol, triglyceride in the blood and uric acid, pH value in the urine were compared. Results:The total clinical effective rate was 93.3% in the treatment group, and 90.0% in the control group. There is no significant difference between two groups (p>0.05). The uric acid in both two groups had decreased after treatment. There are no significant difference between two groups(p>0.05). And in compare with the control group, the herbal decoction can promote the excretion of uric acid, higher the pH values, lower the total cholesterol, triglyceride. Conclusion:The effect of Bu-shen-xie-zhuo-jie-du decoction in lowering the blood uric acid is equal to the effect of allopurinol. However, the herbal decoction can also promote the excretion of uric acid, higher the pH values, lower the total cholesterol and triglyceride. So Bu-shen-xie-zhuo-jie-du decoction is an effective decoction in the treatment of hyperuricemia and should be recommended for a wider use.
本课题根据李富玉教授的临证经验,进行补肾泄浊解毒饮治疗高尿酸血症的临床研究。目的：通过观察补肾泄浊解毒饮和别嘌呤醇治疗高尿酸血症的临床疗效,及治疗前后对血尿酸(SUA)、尿尿酸(UUA)、尿pH值、血清总胆固醇(TCH)和甘油三酯(TG)等指标的影响,进而评价补肾泄浊解毒饮治疗高尿酸血症的临床疗效。方法：将符合高尿酸血症诊断标准的60例患者随机分为中药治疗组30例和别嘌呤醇组30例。中药治疗组给予补肾泄浊解毒饮,口服；西药对照组给予别嘌呤醇片,口服,4周为一个疗程,治疗一个疗程后观察治疗前后临床疗效,并对血尿酸、尿尿酸、尿pH值、血清总胆固醇和甘油三酯等指标进行比较。结果：中药治疗组临床总有效率93.3%,别嘌呤醇组临床总有效率90.0%,两组比较,无显著性差异(P>0.05)；中药治疗组和别嘌呤醇组两组在降低血尿酸方面,各自进行治疗前后的对比,均有显著性差异(P<0.05),但两组进行治疗后血尿酸水平的对比,则无显著性差异(P>0.05),在其他各项观察指标中,中药治疗组能增加尿尿酸的排泄,提高尿pH值,降低总胆固醇、甘油三酯,而别嘌呤醇组则无此作用。
结论：补肾泄浊解毒饮具有降低血尿酸的作用,其降低血尿酸的效果与别嘌呤醇相当,同时补肾泄浊解毒饮还有增加尿尿酸排泄、提高尿pH值、降低总胆固醇及甘油三酯等作用,因此,补肾泄浊解毒饮是治疗高尿酸血症的有效方药之一,值得进一步研究开发及推广应用。
Professor Li Fu-yu is a man of strong moral fiber and good medical technology. He has rich experience in diagnosis, treatment and prevention of difficult and complicated diseases. According to many years'clinical experience, he propounds a theory of diseases induced by Toxin. Recently, the rate of hyperuricemia has increased. Professor Li thinks difficult and complicated diseases are usually caused by toxin, so those diseases can be treated by relieving internal toxin. Hyperuricemia is also a subclinical disease. Based on the modern medical research in the formation mechanism, pathogenic characteristics and epidemiological investigation and Prof. Li's clinical experience, he proposes a view that the essential pathogenesis of hyperuricemia is kidney deficiency and toxin stasis. Toxin plays an important role in the development of hyperuricemia. Furthermore, he points out that tonifying the kidney and relieving internal toxin are two principles of treatment. He also emphasizes protection before the onset and preventing disease from exacerbating in the treatment of hyperuricemia.
This study was a clinical research aimed to evaluate the efficacy of tonifying the kidney and relieving internal toxin on the treatment of hyperuricemia. Objective:To observe the clinical efficacy of Bu-shen-xie-zhuo-jie-du decoction on hyperuricemia by comparison of uric acid, total cholesterol, triglyceride in the blood and acidum uricum, pH value in the urine before and after treatment. Methods:60 patients with a diagnosis of hyperuricemia were randomly divided into two groups. There are 30 patients in control group treated with allopurinol, and 30 patients in treatment group treated with herbal decoction. Four weeks was a treatment course. After a course, the clinical effects were evaluated and the indexes of uric acid, total cholesterol, triglyceride in the blood and uric acid, pH value in the urine were compared. Results:The total clinical effective rate was 93.3% in the treatment group, and 90.0% in the control group. There is no significant difference between two groups (p>0.05). The uric acid in both two groups had decreased after treatment. There are no significant difference between two groups(p>0.05). And in compare with the control group, the herbal decoction can promote the excretion of uric acid, higher the pH values, lower the total cholesterol, triglyceride. Conclusion:The effect of Bu-shen-xie-zhuo-jie-du decoction in lowering the blood uric acid is equal to the effect of allopurinol. However, the herbal decoction can also promote the excretion of uric acid, higher the pH values, lower the total cholesterol and triglyceride. So Bu-shen-xie-zhuo-jie-du decoction is an effective decoction in the treatment of hyperuricemia and should be recommended for a wider use.
引文
[1]叶任高,陆再英.内科学[M].北京：人民卫生出版社,2004：862-868.
[2]翁维良,房书亭.临床中药学[M].河南科学技术出版社,第1版,1998：740,1257,414.
[3]林凤平,任开明,宋恩峰,等.威灵仙对尿酸性肾病大鼠的实验研究[J].中成药.2006,28(6)：845.
[4]雷载权.中药学[M],上海：上海科学技术出版社,第1版,1999：118.
[5]刘恩琪.益气养阴清热利水法治疗痛风性肾病临床疗效观察[J].中国医刊,1999,34(3)：46-47.
[6]张海德,黄玉林,何继芹.丹参二萜醌对黄嘌呤氧化酶活性的抑制作用[J].中国药理学与毒理学杂志.2007,21(3)：178.
[7]曾平.丹参注射液在治疗痛风中的应用[J].中国医学杂志.2007,5(4)：50.
[8]徐霞,张小莉,闫素清,等.冬凌草甲素等二萜类化合物的抗氧化作用[J].海峡药学.2002,14(6)：30.
[9]莫艳珠,潘炉台,续梅,等.Guidongnin抗炎,抑菌药理作用研究[J].贵州科学.1996,4：50.
[10]许小晶,万牡华,欧阳健明,等.尿液pH变化与尿液中纳米微晶组分的关系[J].光谱学与光谱分析.2009,29(1)：275.
[11]Nicar MJ, HsuMC. Johnson T. et al. Laboratory Medicine,1987,18(6): 382.
[12]Konigsberge E.Wang Z H. Monatshefte Fur Chemie,1999,130(9):1067.
[13]Shekarriz B,Stoller ML.Uric acid nephrolithiasis:current concepts and controversies[J]. J Urol,2002,168(4):1307-1314.
[14]赵水平.临床血脂学[M].长沙：湖南科学技术出版社,1997,86-87.
[15]徐晓菲,姜宝法,张源朝,等.山东沿海地区人群血尿酸水平及其在痛风筛检中的意义.山东医科大学学报,2000,138：339-341.
[16]柳洁,康文娟,程瑞迎,等.肥胖的痛风性关节炎患者血尿酸代谢与胰岛素抵抗的相关性分析.中华风湿病学杂志.2001,5：331-332.
[17]林树无,姚敏,徐旺达,等.血尿酸浓度与冠心病患者相关临床分析[J].中国实用内科杂志,2005,25(6)：553.
[18]陈灏珠.实用内科学[M].北京：人民卫生出版社,2005：2603-2605.
[19]姚宗良,姜胜杰,刘慧,等.青岛市沿海社区人群高尿酸血症与痛风的流行病学调查[J].中华风湿病学杂志.2007,11(11)：674.
[20]毛玉山.无症状高尿酸血症的研究进展[J].现代实用医学.2005,17(3)：189.
[21]Campion EW, Glynn RJ, DeLabry LO.Asymptomatic hyp eruricemia. Risks and consequences in the normative aging study[J].Am J Med,1987,82(3): 421-426.
[22]Emmerson B. T. Drug therapy:the manage of gout[J]. N Engl J Med,1996, 334(7):445-451.
[23]Rott KT, Agudelo CA. Gout[J]. J Am Med Assoc,2003,289(21):2857-2860.
[24]Nakagawa T,Hu H,Zharikov S,et al.A causal role for uricacid in fructose-induced metabolic syndrome[J].Am J Physwl Real Physiol,2006, 290(3):F625-F631.
[25]Fang J. Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study,1971-1992.National Health and Nutrition Examination Survey[J].J Am Med Assoc,2000,283:2404-2410.
[26]Hayden MR,Tyagi SC. Uric acid:a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 iabetes mellitus:the urate redox shutde[J].Nutr Metab (Lond),2004,1(1):10-25.
[27]MazzaliM, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension, 2001,38:1101-1106.
[28]Mardianov I,Balabolkin MI,Markov DS.Osnovnye prichiny giperunkemii prisakharnom diabetes.Main causes of hyperuricemai in diabetes mellitus [J].TerArkh,2000;72:55-58.
[29]Shekarriz B,Stoller ML.Uric acid nephrolithiasis:current concepts and controversies [J]. J Urol,2002,168(4):1307-1314.
[30]张娴娴.孙维峰教授诊治无症状高尿酸血症经验拾萃.贵阳中医学院学报.2010,32(1)：11.
[31]朱维平,赵云升,张茂全.清肝化浊饮治疗高尿酸血症的临床观察[J].光明中医,2008,23(5)：574-577.
[32]李萌.试论高尿酸血症从脾肾论治[J].中国中医药杂志,2008,6(3)：26.
[33]李俊.高尿酸血症中医治疗体会[J],中国医学创新,2009,6(16)：24.
[34]陈黎明.利湿化浊方治疗高尿酸血症38例临床观察[J].云南中医中药杂志.2008,29(10)：10.
[35]刘同库,马鸿雁.高尿酸血症一个未被重视的心血管病危险因素[J].心肺血管病杂志,2008,27(2)：122-123.
[1]陈灏珠.实用内科学[M].北京：人民卫生出版社,2005：2603-2605.
[2]叶任高.内科学[M].北京：人民卫生出版社,2000：877-883.
[3]Culleton BF,Larson Mg,Kannel WB,et al.Serum uric acid and risk for cardiovascular disease and deat h[J].The Framingham Heart Study. Ann Intern Med,1999,131:7-13.
[4]古萍.广州市体检人群高尿酸血症患病情况及相关疾病分析[J].中国热带医学,2006,6(6)：1082-1084.
[5]田小草,逢增昌,鲍国春,等.青岛市居民高尿酸血症患病及影响因素分析[J].中国公共卫生.2008,24(3)：361.
[6]陈玉群.重庆市城市体检人群高尿酸血症的患病情况及相关因素分析[J].第三军医大学学报.2008,30(11)：1017.
[7]Ames BN, Cathcart R,Schwiers E,et al.Uric acid provides an antloxidant defense in humans against oxidant-and radical-caused aging and cancer a hypothesis[J]. Proc Natl Acad Sci USA.981,78(11):6858.
[8]Sergei V. Spitsin, Gwen S. Scott, Tatiana Mikheeva. Comparison of uric acid and ascorbic acid in protection against EAE[J]. Free Radical Biology & Medicine.2002,33(10):1363-1371.
[9]Blemings, Beth Stinefelt, Stephen S. et al. Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid[J]. Annals of Clinical & Laboratory Science.2005,35(1):37-45.
[10]Netea MG, Kullberg BJ, Block WL, et al. The role of hypemricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice[J]. Blood.1997,89:577-582.
[11]Richter C,Park J,Ames B. Normal oxidative damage to mitochondrial and nuclear DNA is extensive[J].PNAS USA.1977,85:6565-6567.
[12]Jerome, KR, Corey L.The danger within[J].N.Engl.J.Med.2004,350:411-412.
[13]de la Sierra A, Lluch MM, Coca A, et al. Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients[J].Clin sci(Lond).1996,91:155-161.
[14]Watanabe S, Kang DH, Feng L.Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity[J].Hypertension.2002,40(3):355-60.
[15]陈香美等.尿酸性肾病[J].中华内科杂志.2005,44(3)：231-233.
[16]Garcia-Pavia P,Torres RJ,Rivero M,et al.Phosphoribosyl-pyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young wonman. Arthritis Rheum.2003,48:2036-2041.
[17]Jinnah HA,De Gregorio L,Harris JC,et al.The spectrum of inherited mutations causing HPRT deficiency:75 new cases and a review of 196 previously reported cases. Mutat Res.2000,463:309-326.
[18]钱芸娟,郝文科.高尿酸血症对肾损害的防治[J].中华临床医师杂志(电子版).2008,2(4)：12.
[19]孙瑞霞,李长贵,苗志敏.人肾脏尿酸盐转运分子机制研究进展.国外医学：泌尿系统分册.2005,25(2)：281-284.
[20]Hyink DP,Rappoport JZ,Wilson PD,et al.Expression of the urate transporter/channel is developmentally regulated in human kidneys. Am J Physiol Renal Physiol,2001,281:875-886.
[21]Yamamoto T, Moriwaki Y,Takahashi S.Efect of ethanol on metabolism of pufine bases (hypoxanthine, xanthine, and uric acid). Chin Chim Acta,2005, 356(1-2):35-57.
[22]蒋光荣,郑恒,邵少慰,等.高尿酸血症的研究进展[J].医学综述,2008,14(11)：1674-1675
[23]SO A.Recent advances in the pathophysiology of hyperuricemia and gout[J].Rev Med Suisse.2007,3(103):722-724.
[24]Feig DI,Johnson RJ.The role of uric acid in pediatric hypertension[J].J Ren Nutr.2007,17(1):79-83.
[25]Sanchez-Lozada LG,Tapia E,Lopez-Molina R,et al.Effects of acute and chronic L-arginine treatmentin experimental hyperuricemia[J].Am J Physiol Rena Physiol.2007,292 (4):1238-1244.
[26]Roncal CA,Mu W,Croker B,et al.Effect of elevated serum uric acid on cisplatin-induced acute renal failure[J].Am J Physiol Renal Physiol,2007, 292(1):116-122.
[27]Giovannini I,Chiarla C,Giuliante F,et al.Serum uric acid, creatinine.and the assessment of antioxidant capacity in critical illness[J].Crit Care.2006, 10(5):421-423.
[28]Patschan D,Patschan S,Gobe GG,et al.Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells[J].J Am Soc Nephrol.2007, 18(5):1516-1524.
[29]Baker JF,Krishnan E,Chen L,et al. Serum uric acid and cardiovascular disease:recent developments, and where do they leave us?[J]. Am J Med, 2005,118(8):816-826.
[30]Cheung KJ, Tzameli I, Pissios P, et al. Xantlline oxidoreductase is a regulator of adipogenesis and PPARgamma activity[J]. Cell Metab.2007,5(2):115-128.
[31]Sautin YY, Nakagawa T, Zharikov S, et al.Adverse effects of the classical antioxidant uric acid in adipocytes NADPH oxidase-mediated oxidative/nitrosative stress [J].Am J Physiol Cell Physiol,2007,293(2): 584-596.
[32]YuJun-wen,LuJin-bo,Zhang Xiao-juan, et al.13,324 resident's serum uric acid in Foshan area and there lated index analysis [J].chineseJournalof Integrated Traditional and Western NePhrology,2005,7(7):401-403(InChinese).
[33]Moszner N,Fischer UK.Bis-(acrylamide)s as new cross-linkers for resinbased composite restoratives [J]. Dent Mater.2006,22(12):1157-1162.
[34]王东升,郑虹,米树华.代谢综合征患者的尿酸与血脂相关性研究[J].中国综合临床.2006,22(8)：710-711.
[35]Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia[J].Am J Med.2007,120(5):442-447.
[36]Tsouli SQLiberopoulos EN,Mikhailidis DP,et al.Elevated serum uric acid levels in metabolic syndrome:an active component or an innocent bystander? [J].Metabolism.2006,55(10):1293-1301.
[37]何立群,聂永江,邹士林.新型尿酸肾病动物模型的建立.上海实验动物科学.2001,21(1)：22-24.
[38]张超,曹克光,扬紫青,等.高尿酸血症及尿酸性肾病动物模型的建立及应用[J].实验动物科学与管理.1999,16：17.
[39]陈香美,汤力.痛风肾与慢性肾功能衰竭.中华实用内科杂志.1997,17(6)：328-330.
[40]Roncal CA,Mu W,Croker B,et al.Effect of elevated serum uric acid on cisplatin-induced acute renal failure[J].Am J Physiol Renal Physiol.2007, 292(1):116-122.
[41]滕森新,郑洁(译).高尿酸血症[J].日本医学介绍.2001,22(7)：307-309.
[42]黄麦华,王中东,张国芹.120例高尿酸血症患者血脂与肾功能结果分析[J].泰山医学院学报.2006,27(2)：170-171.
[43]Sanchez-Lozada LQTapia E,Lopez-Molina R,et al.Effects of acute and chronic L-arginine treatmentin experimental hyperuricemia[J].Am J Physiol Rena Physiol.2007,292 (4):1238-1244.
[44]Syrjanen J,Mustonen J,Pastermack A Hypertrigly ceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant,2000,15(1):34-42
[44]杨菊贤,陈鑫,等.早期干预高尿酸血症与心脑血管疾病的预防[J].健康教育与健康促进,2008,3(1)：52.
[45]Alderman MH,Cohen H,Madhavan S,et al.Serum uric acid and cardiovascular events in successfully treated hypertensive patients[J]. Hypertension. 1999,34(1):144-150.
[46]Baker JF,Krishnan E,Chen L,et al.Serum uric acid and cardiovascular disease:recent developments,and where do they leave us? [J].Am J Med.2005,118(8):816-826.
[47]Hoieggen A, Alderman MH, Kjeldsen SE, et al.The impact of serum uric acid on cardiovascular outcomes in the LIFE study[J]. Kidney Int.2004,65(3): 1041-1049.
[48]Gertler MM,Garn SM.Levine SA.Serum uric acid in relation to age and physique in health and in coronary heart disease[J].Ann Intern Med. 1951,34(6):1421-1431.
[49]Fang J, Alderman MH. Serum uric acid and cardiovacular mortality:The NHANESI epidemiologic follow-up study[J].JAMA,2000,283:2404-2410.
[50]Karagiannis A,Mikhailidis DP,Tziomalos K,et al.Serum uric acid as an independent predictor of early death after acute stroke.Circ J,2007, 71:1120-1127.
[51]Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure:validation and application in metabolic, functional, and hemodynamic staging. Circulation,2003,107:1991-1997.
[52]张红叶.血清尿酸与四年后血压变化及高血压病关系[J].高血压病杂志.2001,9(5)：160-163.
[53]Cannon PJ,Stason WB, Demartini F E,et al.Hyperuricemia in primary and renal hypertension[J].N Engl J Med.1966,275:457-464.
[54]Jossa F, Farinaro E,Panico S,et al.Serum uric acid and hypertension:the Olivetti heart study.J Hum Hypertens,1994,8:667-681.
[55]Zhu Wen-hua,Fang Li-zheng,Li Nan,et al.Eaech disorder in Metabolic syndrome on the influence of hyperuricemia[J].Chinses Journal of Internal Medicine.2006,45:228-229(InChinese).
[56]Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willierbrand factor predicts adverse outcome in unstable coronary artery disease:beneficial effects of enoxaparin[J].Circulation.1998,98(4):294-299.
[57]Maliavskaia SI,Lebedev AV,Termovskaia VA. Chronic asymptomatic hyperuricemia as a marker of atherogenic risk in children[J].Kardiologiia. 2007,47(3):62-66.
[58]Sun Y,Lin CH,Lu CJ, et al. Carotid atherosclerosis, intinamedia thickness and risk factors an analysis of 1781 asymptomatic subjects in Taiwan[J]. Atherosclerosis,2002,164(1):89-94.
[59]陈予新.高尿酸血症与高血压关系临床分析[J].中国现代医药杂志,2004,6(4)：51-52.
[60]Beevers DQLip GY.Is uric acid really an independent cardiovascular risk factor[J].Lancet.1998,352:1556.
[61]Nieto FJ,Iribarren C,Gross MD, et al. Uric acid and serum antioxidant capacity:a reaction to atherosclerosis? [J].Atherosclerosis.2000,148(1): 131-139.
[62]龙配国.高尿酸血症对缺血性脑血管疾病发生的影响[J].疑难病杂志.2007,6(8)：464.
[63]陈立杰,李和永.高尿酸血症与缺血性卒中[J].国际脑血管病杂志,2006,14(12)：922-924.
[64]Li Hong-chao.Wu Lu-sheng.HyPeruricemia and Gout and Metabolic Syndrome[J].Journal of Clinical Internal Medicine.2005,22:797-799(In Chinese).
[65]Tsunoda S,Kamide K,Minami J,et al.Decreases in serum uric acid by a melioration of insulin resistance in over weight hypertensive patients:efect of a low energy diet and an insulin sensitizing agent. Am J Hypertens.2002,15: 697-701.
[66]高琳,许晴晴,唐诗伟,等.2型糖尿病微血管病变患者血尿酸与胰岛素抵抗的关系.陕西医学杂志.2003,32：431-432.
[67]Lai SW,Li T,Ng K. hyperuricemia and its related factors in Tai ses middleaged adults[J].Int J Pract,2002,8(1):56-60.
[68]Wortmann RL.Gout and hyperuricemia [J].Curr Opin Rheumatol,2002, 14(3):281-286.
[69]Cardona F,Tinahones FJ,Collantes E,et al.The elevated prevalence of apolipoprotein E in patients with gout is associated with reduced renal excretion of urates[J]. Rheum,2003,42:468-472.
[70]倪忠根,曹克光.血脂与血尿酸的关系[J].长春中医药大学学报,2008,24(1) ：42.
[71]李萌.试论高尿酸血症从脾肾论治[J].中国中医药杂志2008,6(3)：26.
[72]李承恩,谈文峰.“秦虎汤”治疗无症状性高尿酸血症48例,江苏中医药,2004,25(4)：22.
[73]赵泉霖,郝亮.原发性高尿酸血症辨治初探,山东中医杂志,2005,24(8)：453.
[74]朱平,曹克光.治疗痛风及高尿酸血症经验宋平[J].中医药临床杂志.2005,17(5)：435-436
[75]张永生.姜良铎教授治疗痛风经验 [J].北京中医药大学学报.2002,(2)：61-62.
[76]季锡林,季建军,朱晓俊,等.健脾化浊汤治疗原发性HUA31例[J].浙江中医杂志.2006,41(3)：149.
[77]姜蔓萍,李中原.辨证治疗HUA疗效分析[J].河南中医.2005,25(2)：53.
[78]武蕾,何红涛,汪慰寒,等.利湿降浊法治疗HUA30例临床观察[J].中华现代实用医药杂志.2004,4(17)：2312.
[79]馆寿明.平胃散合五苓散治疗HUA36例[J].现代中西医结合杂志.2008,17(15)：690.
[80]陆艳萍,宋海澄,舒荣,等.除湿化瘀法治疗HUA临床观察[J].中国煤炭工业医学杂志.2007,10(10)：1205.
[81]陈世伟,李卫青,孙劲松,等.平胃降浊汤治疗HUA疗效观察[J].山西中医.2007,23(3)：17-18.
[82]黄德光.中西医结合治疗HUA77例疗效观察[J].湖南中医杂志.2007,23 (2) ：8-9.
[83]陆飞鹏.中西医结合治疗高尿酸血症28例.现代中西医结合杂志,2002,11(10)：929.
[2]翁维良,房书亭.临床中药学[M].河南科学技术出版社,第1版,1998：740,1257,414.
[3]林凤平,任开明,宋恩峰,等.威灵仙对尿酸性肾病大鼠的实验研究[J].中成药.2006,28(6)：845.
[4]雷载权.中药学[M],上海：上海科学技术出版社,第1版,1999：118.
[5]刘恩琪.益气养阴清热利水法治疗痛风性肾病临床疗效观察[J].中国医刊,1999,34(3)：46-47.
[6]张海德,黄玉林,何继芹.丹参二萜醌对黄嘌呤氧化酶活性的抑制作用[J].中国药理学与毒理学杂志.2007,21(3)：178.
[7]曾平.丹参注射液在治疗痛风中的应用[J].中国医学杂志.2007,5(4)：50.
[8]徐霞,张小莉,闫素清,等.冬凌草甲素等二萜类化合物的抗氧化作用[J].海峡药学.2002,14(6)：30.
[9]莫艳珠,潘炉台,续梅,等.Guidongnin抗炎,抑菌药理作用研究[J].贵州科学.1996,4：50.
[10]许小晶,万牡华,欧阳健明,等.尿液pH变化与尿液中纳米微晶组分的关系[J].光谱学与光谱分析.2009,29(1)：275.
[11]Nicar MJ, HsuMC. Johnson T. et al. Laboratory Medicine,1987,18(6): 382.
[12]Konigsberge E.Wang Z H. Monatshefte Fur Chemie,1999,130(9):1067.
[13]Shekarriz B,Stoller ML.Uric acid nephrolithiasis:current concepts and controversies[J]. J Urol,2002,168(4):1307-1314.
[14]赵水平.临床血脂学[M].长沙：湖南科学技术出版社,1997,86-87.
[15]徐晓菲,姜宝法,张源朝,等.山东沿海地区人群血尿酸水平及其在痛风筛检中的意义.山东医科大学学报,2000,138：339-341.
[16]柳洁,康文娟,程瑞迎,等.肥胖的痛风性关节炎患者血尿酸代谢与胰岛素抵抗的相关性分析.中华风湿病学杂志.2001,5：331-332.
[17]林树无,姚敏,徐旺达,等.血尿酸浓度与冠心病患者相关临床分析[J].中国实用内科杂志,2005,25(6)：553.
[18]陈灏珠.实用内科学[M].北京：人民卫生出版社,2005：2603-2605.
[19]姚宗良,姜胜杰,刘慧,等.青岛市沿海社区人群高尿酸血症与痛风的流行病学调查[J].中华风湿病学杂志.2007,11(11)：674.
[20]毛玉山.无症状高尿酸血症的研究进展[J].现代实用医学.2005,17(3)：189.
[21]Campion EW, Glynn RJ, DeLabry LO.Asymptomatic hyp eruricemia. Risks and consequences in the normative aging study[J].Am J Med,1987,82(3): 421-426.
[22]Emmerson B. T. Drug therapy:the manage of gout[J]. N Engl J Med,1996, 334(7):445-451.
[23]Rott KT, Agudelo CA. Gout[J]. J Am Med Assoc,2003,289(21):2857-2860.
[24]Nakagawa T,Hu H,Zharikov S,et al.A causal role for uricacid in fructose-induced metabolic syndrome[J].Am J Physwl Real Physiol,2006, 290(3):F625-F631.
[25]Fang J. Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study,1971-1992.National Health and Nutrition Examination Survey[J].J Am Med Assoc,2000,283:2404-2410.
[26]Hayden MR,Tyagi SC. Uric acid:a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 iabetes mellitus:the urate redox shutde[J].Nutr Metab (Lond),2004,1(1):10-25.
[27]MazzaliM, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension, 2001,38:1101-1106.
[28]Mardianov I,Balabolkin MI,Markov DS.Osnovnye prichiny giperunkemii prisakharnom diabetes.Main causes of hyperuricemai in diabetes mellitus [J].TerArkh,2000;72:55-58.
[29]Shekarriz B,Stoller ML.Uric acid nephrolithiasis:current concepts and controversies [J]. J Urol,2002,168(4):1307-1314.
[30]张娴娴.孙维峰教授诊治无症状高尿酸血症经验拾萃.贵阳中医学院学报.2010,32(1)：11.
[31]朱维平,赵云升,张茂全.清肝化浊饮治疗高尿酸血症的临床观察[J].光明中医,2008,23(5)：574-577.
[32]李萌.试论高尿酸血症从脾肾论治[J].中国中医药杂志,2008,6(3)：26.
[33]李俊.高尿酸血症中医治疗体会[J],中国医学创新,2009,6(16)：24.
[34]陈黎明.利湿化浊方治疗高尿酸血症38例临床观察[J].云南中医中药杂志.2008,29(10)：10.
[35]刘同库,马鸿雁.高尿酸血症一个未被重视的心血管病危险因素[J].心肺血管病杂志,2008,27(2)：122-123.
[1]陈灏珠.实用内科学[M].北京：人民卫生出版社,2005：2603-2605.
[2]叶任高.内科学[M].北京：人民卫生出版社,2000：877-883.
[3]Culleton BF,Larson Mg,Kannel WB,et al.Serum uric acid and risk for cardiovascular disease and deat h[J].The Framingham Heart Study. Ann Intern Med,1999,131:7-13.
[4]古萍.广州市体检人群高尿酸血症患病情况及相关疾病分析[J].中国热带医学,2006,6(6)：1082-1084.
[5]田小草,逢增昌,鲍国春,等.青岛市居民高尿酸血症患病及影响因素分析[J].中国公共卫生.2008,24(3)：361.
[6]陈玉群.重庆市城市体检人群高尿酸血症的患病情况及相关因素分析[J].第三军医大学学报.2008,30(11)：1017.
[7]Ames BN, Cathcart R,Schwiers E,et al.Uric acid provides an antloxidant defense in humans against oxidant-and radical-caused aging and cancer a hypothesis[J]. Proc Natl Acad Sci USA.981,78(11):6858.
[8]Sergei V. Spitsin, Gwen S. Scott, Tatiana Mikheeva. Comparison of uric acid and ascorbic acid in protection against EAE[J]. Free Radical Biology & Medicine.2002,33(10):1363-1371.
[9]Blemings, Beth Stinefelt, Stephen S. et al. Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid[J]. Annals of Clinical & Laboratory Science.2005,35(1):37-45.
[10]Netea MG, Kullberg BJ, Block WL, et al. The role of hypemricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice[J]. Blood.1997,89:577-582.
[11]Richter C,Park J,Ames B. Normal oxidative damage to mitochondrial and nuclear DNA is extensive[J].PNAS USA.1977,85:6565-6567.
[12]Jerome, KR, Corey L.The danger within[J].N.Engl.J.Med.2004,350:411-412.
[13]de la Sierra A, Lluch MM, Coca A, et al. Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients[J].Clin sci(Lond).1996,91:155-161.
[14]Watanabe S, Kang DH, Feng L.Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity[J].Hypertension.2002,40(3):355-60.
[15]陈香美等.尿酸性肾病[J].中华内科杂志.2005,44(3)：231-233.
[16]Garcia-Pavia P,Torres RJ,Rivero M,et al.Phosphoribosyl-pyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young wonman. Arthritis Rheum.2003,48:2036-2041.
[17]Jinnah HA,De Gregorio L,Harris JC,et al.The spectrum of inherited mutations causing HPRT deficiency:75 new cases and a review of 196 previously reported cases. Mutat Res.2000,463:309-326.
[18]钱芸娟,郝文科.高尿酸血症对肾损害的防治[J].中华临床医师杂志(电子版).2008,2(4)：12.
[19]孙瑞霞,李长贵,苗志敏.人肾脏尿酸盐转运分子机制研究进展.国外医学：泌尿系统分册.2005,25(2)：281-284.
[20]Hyink DP,Rappoport JZ,Wilson PD,et al.Expression of the urate transporter/channel is developmentally regulated in human kidneys. Am J Physiol Renal Physiol,2001,281:875-886.
[21]Yamamoto T, Moriwaki Y,Takahashi S.Efect of ethanol on metabolism of pufine bases (hypoxanthine, xanthine, and uric acid). Chin Chim Acta,2005, 356(1-2):35-57.
[22]蒋光荣,郑恒,邵少慰,等.高尿酸血症的研究进展[J].医学综述,2008,14(11)：1674-1675
[23]SO A.Recent advances in the pathophysiology of hyperuricemia and gout[J].Rev Med Suisse.2007,3(103):722-724.
[24]Feig DI,Johnson RJ.The role of uric acid in pediatric hypertension[J].J Ren Nutr.2007,17(1):79-83.
[25]Sanchez-Lozada LG,Tapia E,Lopez-Molina R,et al.Effects of acute and chronic L-arginine treatmentin experimental hyperuricemia[J].Am J Physiol Rena Physiol.2007,292 (4):1238-1244.
[26]Roncal CA,Mu W,Croker B,et al.Effect of elevated serum uric acid on cisplatin-induced acute renal failure[J].Am J Physiol Renal Physiol,2007, 292(1):116-122.
[27]Giovannini I,Chiarla C,Giuliante F,et al.Serum uric acid, creatinine.and the assessment of antioxidant capacity in critical illness[J].Crit Care.2006, 10(5):421-423.
[28]Patschan D,Patschan S,Gobe GG,et al.Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells[J].J Am Soc Nephrol.2007, 18(5):1516-1524.
[29]Baker JF,Krishnan E,Chen L,et al. Serum uric acid and cardiovascular disease:recent developments, and where do they leave us?[J]. Am J Med, 2005,118(8):816-826.
[30]Cheung KJ, Tzameli I, Pissios P, et al. Xantlline oxidoreductase is a regulator of adipogenesis and PPARgamma activity[J]. Cell Metab.2007,5(2):115-128.
[31]Sautin YY, Nakagawa T, Zharikov S, et al.Adverse effects of the classical antioxidant uric acid in adipocytes NADPH oxidase-mediated oxidative/nitrosative stress [J].Am J Physiol Cell Physiol,2007,293(2): 584-596.
[32]YuJun-wen,LuJin-bo,Zhang Xiao-juan, et al.13,324 resident's serum uric acid in Foshan area and there lated index analysis [J].chineseJournalof Integrated Traditional and Western NePhrology,2005,7(7):401-403(InChinese).
[33]Moszner N,Fischer UK.Bis-(acrylamide)s as new cross-linkers for resinbased composite restoratives [J]. Dent Mater.2006,22(12):1157-1162.
[34]王东升,郑虹,米树华.代谢综合征患者的尿酸与血脂相关性研究[J].中国综合临床.2006,22(8)：710-711.
[35]Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia[J].Am J Med.2007,120(5):442-447.
[36]Tsouli SQLiberopoulos EN,Mikhailidis DP,et al.Elevated serum uric acid levels in metabolic syndrome:an active component or an innocent bystander? [J].Metabolism.2006,55(10):1293-1301.
[37]何立群,聂永江,邹士林.新型尿酸肾病动物模型的建立.上海实验动物科学.2001,21(1)：22-24.
[38]张超,曹克光,扬紫青,等.高尿酸血症及尿酸性肾病动物模型的建立及应用[J].实验动物科学与管理.1999,16：17.
[39]陈香美,汤力.痛风肾与慢性肾功能衰竭.中华实用内科杂志.1997,17(6)：328-330.
[40]Roncal CA,Mu W,Croker B,et al.Effect of elevated serum uric acid on cisplatin-induced acute renal failure[J].Am J Physiol Renal Physiol.2007, 292(1):116-122.
[41]滕森新,郑洁(译).高尿酸血症[J].日本医学介绍.2001,22(7)：307-309.
[42]黄麦华,王中东,张国芹.120例高尿酸血症患者血脂与肾功能结果分析[J].泰山医学院学报.2006,27(2)：170-171.
[43]Sanchez-Lozada LQTapia E,Lopez-Molina R,et al.Effects of acute and chronic L-arginine treatmentin experimental hyperuricemia[J].Am J Physiol Rena Physiol.2007,292 (4):1238-1244.
[44]Syrjanen J,Mustonen J,Pastermack A Hypertrigly ceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant,2000,15(1):34-42
[44]杨菊贤,陈鑫,等.早期干预高尿酸血症与心脑血管疾病的预防[J].健康教育与健康促进,2008,3(1)：52.
[45]Alderman MH,Cohen H,Madhavan S,et al.Serum uric acid and cardiovascular events in successfully treated hypertensive patients[J]. Hypertension. 1999,34(1):144-150.
[46]Baker JF,Krishnan E,Chen L,et al.Serum uric acid and cardiovascular disease:recent developments,and where do they leave us? [J].Am J Med.2005,118(8):816-826.
[47]Hoieggen A, Alderman MH, Kjeldsen SE, et al.The impact of serum uric acid on cardiovascular outcomes in the LIFE study[J]. Kidney Int.2004,65(3): 1041-1049.
[48]Gertler MM,Garn SM.Levine SA.Serum uric acid in relation to age and physique in health and in coronary heart disease[J].Ann Intern Med. 1951,34(6):1421-1431.
[49]Fang J, Alderman MH. Serum uric acid and cardiovacular mortality:The NHANESI epidemiologic follow-up study[J].JAMA,2000,283:2404-2410.
[50]Karagiannis A,Mikhailidis DP,Tziomalos K,et al.Serum uric acid as an independent predictor of early death after acute stroke.Circ J,2007, 71:1120-1127.
[51]Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure:validation and application in metabolic, functional, and hemodynamic staging. Circulation,2003,107:1991-1997.
[52]张红叶.血清尿酸与四年后血压变化及高血压病关系[J].高血压病杂志.2001,9(5)：160-163.
[53]Cannon PJ,Stason WB, Demartini F E,et al.Hyperuricemia in primary and renal hypertension[J].N Engl J Med.1966,275:457-464.
[54]Jossa F, Farinaro E,Panico S,et al.Serum uric acid and hypertension:the Olivetti heart study.J Hum Hypertens,1994,8:667-681.
[55]Zhu Wen-hua,Fang Li-zheng,Li Nan,et al.Eaech disorder in Metabolic syndrome on the influence of hyperuricemia[J].Chinses Journal of Internal Medicine.2006,45:228-229(InChinese).
[56]Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willierbrand factor predicts adverse outcome in unstable coronary artery disease:beneficial effects of enoxaparin[J].Circulation.1998,98(4):294-299.
[57]Maliavskaia SI,Lebedev AV,Termovskaia VA. Chronic asymptomatic hyperuricemia as a marker of atherogenic risk in children[J].Kardiologiia. 2007,47(3):62-66.
[58]Sun Y,Lin CH,Lu CJ, et al. Carotid atherosclerosis, intinamedia thickness and risk factors an analysis of 1781 asymptomatic subjects in Taiwan[J]. Atherosclerosis,2002,164(1):89-94.
[59]陈予新.高尿酸血症与高血压关系临床分析[J].中国现代医药杂志,2004,6(4)：51-52.
[60]Beevers DQLip GY.Is uric acid really an independent cardiovascular risk factor[J].Lancet.1998,352:1556.
[61]Nieto FJ,Iribarren C,Gross MD, et al. Uric acid and serum antioxidant capacity:a reaction to atherosclerosis? [J].Atherosclerosis.2000,148(1): 131-139.
[62]龙配国.高尿酸血症对缺血性脑血管疾病发生的影响[J].疑难病杂志.2007,6(8)：464.
[63]陈立杰,李和永.高尿酸血症与缺血性卒中[J].国际脑血管病杂志,2006,14(12)：922-924.
[64]Li Hong-chao.Wu Lu-sheng.HyPeruricemia and Gout and Metabolic Syndrome[J].Journal of Clinical Internal Medicine.2005,22:797-799(In Chinese).
[65]Tsunoda S,Kamide K,Minami J,et al.Decreases in serum uric acid by a melioration of insulin resistance in over weight hypertensive patients:efect of a low energy diet and an insulin sensitizing agent. Am J Hypertens.2002,15: 697-701.
[66]高琳,许晴晴,唐诗伟,等.2型糖尿病微血管病变患者血尿酸与胰岛素抵抗的关系.陕西医学杂志.2003,32：431-432.
[67]Lai SW,Li T,Ng K. hyperuricemia and its related factors in Tai ses middleaged adults[J].Int J Pract,2002,8(1):56-60.
[68]Wortmann RL.Gout and hyperuricemia [J].Curr Opin Rheumatol,2002, 14(3):281-286.
[69]Cardona F,Tinahones FJ,Collantes E,et al.The elevated prevalence of apolipoprotein E in patients with gout is associated with reduced renal excretion of urates[J]. Rheum,2003,42:468-472.
[70]倪忠根,曹克光.血脂与血尿酸的关系[J].长春中医药大学学报,2008,24(1) ：42.
[71]李萌.试论高尿酸血症从脾肾论治[J].中国中医药杂志2008,6(3)：26.
[72]李承恩,谈文峰.“秦虎汤”治疗无症状性高尿酸血症48例,江苏中医药,2004,25(4)：22.
[73]赵泉霖,郝亮.原发性高尿酸血症辨治初探,山东中医杂志,2005,24(8)：453.
[74]朱平,曹克光.治疗痛风及高尿酸血症经验宋平[J].中医药临床杂志.2005,17(5)：435-436
[75]张永生.姜良铎教授治疗痛风经验 [J].北京中医药大学学报.2002,(2)：61-62.
[76]季锡林,季建军,朱晓俊,等.健脾化浊汤治疗原发性HUA31例[J].浙江中医杂志.2006,41(3)：149.
[77]姜蔓萍,李中原.辨证治疗HUA疗效分析[J].河南中医.2005,25(2)：53.
[78]武蕾,何红涛,汪慰寒,等.利湿降浊法治疗HUA30例临床观察[J].中华现代实用医药杂志.2004,4(17)：2312.
[79]馆寿明.平胃散合五苓散治疗HUA36例[J].现代中西医结合杂志.2008,17(15)：690.
[80]陆艳萍,宋海澄,舒荣,等.除湿化瘀法治疗HUA临床观察[J].中国煤炭工业医学杂志.2007,10(10)：1205.
[81]陈世伟,李卫青,孙劲松,等.平胃降浊汤治疗HUA疗效观察[J].山西中医.2007,23(3)：17-18.
[82]黄德光.中西医结合治疗HUA77例疗效观察[J].湖南中医杂志.2007,23 (2) ：8-9.
[83]陆飞鹏.中西医结合治疗高尿酸血症28例.现代中西医结合杂志,2002,11(10)：929.